Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-24T10:00:20.240Z Has data issue: false hasContentIssue false
  • English
  • Français

Diagnosis and management of prostate cancer in the older man

Part of: Bespoke shallow archive Weizmann

Published online by Cambridge University Press:  11 May 2010

SRC McCracken ,
GC Durkan ,
RS Pickard  and
CN Robson
SRC McCracken*
Affiliation:
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
GC Durkan
Affiliation:
Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK
RS Pickard
Affiliation:
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
CN Robson
Affiliation:
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
*
Address for correspondence: SRC McCracken, Solid Tumour Target Discovery Group, Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

Prostate cancer is the most common malignancy and the second leading cause of cancer death, in men, in western countries. Prostate cancer is diagnosed in very few people aged younger than 50 years (<0.1% of all patients). The mean age of patients with this disorder is 72–74 years. Most men aged older than 85 years have histological prostate cancer. Androgen deprivation reduces tumour activity in approximately 80% of patients with advanced disease, but most tumours relapse within 2 years to an incurable castrate-resistant state. Treatment options for patients with castrate-resistant prostate cancer are very limited and, even with toxic therapy, such as docetaxel, the life expectancy is only improved by a median of 2 months. Hence earlier diagnosis and improved treatments for prostate cancer are urgently required. Novel drugs, such as Abiratorone acetate and MDV-3100 have shown promise in pre-clinical and early clinical trials, and a number are now in phase III clinical trials, alone or in combination with docetaxel.

Keywords

prostate cancercarcinogenesisandrogenhormone
Type
Clinical geriatrics section
Information
Reviews in Clinical Gerontology , Volume 20 , Issue 3 , August 2010 , pp. 193 - 204
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1McNeal, JE. The zonal anatomy of the prostate. Prostate 1981; 2: 35–49.CrossRefGoogle ScholarPubMed
2Dhom, G. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983; 106: 210–18.CrossRefGoogle ScholarPubMed
3Kirby, RS, Christmas, TJ, Brawer, MK. Prostate Cancer. London: Mosby International Ltd, 2001.Google Scholar
4Sakr, WA, Grignon, DJ, Haas, GP, Heilbrun, LK, Pontes, JE, Crissman, JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 138–44.CrossRefGoogle ScholarPubMed
5Ross, RK. Epidemiology of prostate cancer and bladder cancer: an overview. Cancer Treat Res 1996; 88: 1–11.CrossRefGoogle ScholarPubMed
6Cook, LS, Goldoft, M, Schwartz, SM, Weiss, NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999; 161: 152–55.CrossRefGoogle Scholar
7Akazaki, K, Stemmerman, GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J National Cancer Inst 1973; 50: 1137–44.CrossRefGoogle ScholarPubMed
8Pienta, KJ, Esper, PS. Risk factors for prostate cancer. Annals Internal Med 1993; 118: 793–803.CrossRefGoogle ScholarPubMed
9Ross, RK, Bernstein, L, Lobo, RA, Shimizu, H, Stanczyk, FZ, Pike, MC et al. 5-α-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887–89.CrossRefGoogle ScholarPubMed
10Smith, JR, Freije, D, Carpten, JD, Gronberg, H, Xu, J, Isaacs, SD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371–74.CrossRefGoogle ScholarPubMed
11Carter, BS, Bova, GS, Beaty, TH, Steinberg, GD, Childs, B, Isaacs, WB et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797–802.CrossRefGoogle ScholarPubMed
12Hayes, RB, Ziegler, RG, Gridley, G, Swanson, C, Greenberg, RS, Swanson, GM et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 25–34.Google ScholarPubMed
13Augustsson, K, Skog, K, Jagerstad, M, Dickman, PW, Steineck, G. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet 1999; 353: 703–7.CrossRefGoogle ScholarPubMed
14Wang, Y, Corr, JG, Thaler, HT, Tao, Y, Fair, WR, Heston, WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 1995; 87: 1456–62.CrossRefGoogle ScholarPubMed
15Snowdon, DA, Phillips, RL, Choi, W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984; 120: 244–50.CrossRefGoogle ScholarPubMed
16Giovannucci, E, Ascherio, A, Rimm, EB, Stampfer, MJ, Colditz, GA, Willett, WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767–76.CrossRefGoogle ScholarPubMed
17Heber, D, Lu, QY. Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood) 2002; 227: 920–23.CrossRefGoogle ScholarPubMed
18Gleason, DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125–28.Google ScholarPubMed
19Gleason, DF. Histologic grading of prostate cancer: a perspective. Human Pathology 1992; 23: 273–79.CrossRefGoogle ScholarPubMed
20Humphrey, PA. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology 2004; 17: 292–306.CrossRefGoogle ScholarPubMed
21Lilja, H, Ulmert, D, Vickers, AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268–78.CrossRefGoogle Scholar
22Lilja, H, Ulmert, D, Bjork, T, Becker, C, Serio, AM, Nilsson, JA et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25: 431–36.CrossRefGoogle ScholarPubMed
23Thompson, IM, Pauler, DK, Goodman, PJ, Tangen, CM, Lucia, MS, Parnes, HL et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–46.CrossRefGoogle ScholarPubMed
24Schroder, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Ciatto, S, Nelen, V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–28.CrossRefGoogle Scholar
25Hull, GW, Rabbani, F, Abbas, F, Wheeler, TM, Kattan, MW, Scardino, PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528–34.CrossRefGoogle Scholar
26Kaufman, DS, McDougal, WS, Zietman, AL, Harisinghani, MG, Young, RH. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21–2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy. New Eng J Med 2004; 351: 171–78.CrossRefGoogle ScholarPubMed
27Zelefsky, MJ, Lyass, O, Fuks, Z, Wolfe, T, Burman, C, Ling, CC et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 1998; 16: 3380–85.CrossRefGoogle ScholarPubMed
28Dearnaley, DP, Khoo, VS, Norman, AR, Meyer, L, Nahum, A, Tait, D et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267–72.CrossRefGoogle ScholarPubMed
29Henderson, A, Bott, SR, Sooriakumaran, P, Laing, RW, Langley, SE. Urinary morbidity after 125I brachytherapy of the prostate. BJU Int 2004; 93: 890.CrossRefGoogle ScholarPubMed
30Nilsson, S, Norlen, BJ, Widmark, A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316–81.CrossRefGoogle ScholarPubMed
31Kuhn, JM, Billebaud, T, Navratil, H, Moulonguet, A, Fiet, J, Grise, P et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989; 321: 413–18.CrossRefGoogle ScholarPubMed
32Seidenfeld, J, Samson, DJ, Hasselblad, V, Aronson, N, Albertsen, PC, Bennett, CL et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566–77.CrossRefGoogle ScholarPubMed
33Shahinian, VB, Kuo, YF, Freeman, JL, Goodwin, JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154–64.CrossRefGoogle ScholarPubMed
34Halabi, S, Small, EJ, Kantoff, PW, Kattan, MW, Kaplan, EB, Dawson, NA et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232–37.CrossRefGoogle ScholarPubMed
35Emrich, LJ, Priore, RL, Murphy, GP, Brady, MF. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985; 45: 5173–79.Google ScholarPubMed
36Kantoff, PW, Halabi, S, Conaway, M, Picus, J, Kirshner, J, Hars, V et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506–13.CrossRefGoogle ScholarPubMed
37Stanbrough, M, Bubley, GJ, Ross, K, Golub, TR, Rubin, MA, Penning, TM et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815–25.CrossRefGoogle ScholarPubMed
38Attard, G, Reid, AH, Olmos, D, de Bono, JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009; 69: 4937–40.CrossRefGoogle ScholarPubMed
39Tran, C, Ouk, S, Clegg, NJ, Chen, Y, Watson, PA, Arora, V et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787–90.CrossRefGoogle ScholarPubMed
40Attard, G, Reid, AH, A'Hern, R, Parker, C, Oommen, NB, Folkerd, E et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742–48.CrossRefGoogle ScholarPubMed
41Hobisch, A, Culig, Z, Radmayr, C, Bartsch, G, Klocker, H, Hittmair, A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55: 3068–72.Google ScholarPubMed
42Koivisto, P, Kononen, J, Palmberg, C, Tammela, T, Hyytinen, E, Isola, J et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314–19.Google ScholarPubMed
43Edwards, J, Krishna, NS, Grigor, KM, Bartlett, JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552–56.CrossRefGoogle ScholarPubMed
44Marcelli, M, Ittmann, M, Mariani, S, Sutherland, R, Nigam, R, Murthy, L et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944–49.Google ScholarPubMed
45Tilley, WD, Buchanan, G, Hickey, TE, Bentel, JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2: 277–85.Google ScholarPubMed
46Taplin, ME, Bubley, GJ, Shuster, TD, Frantz, ME, Spooner, AE, Ogata, GK et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Eng J Med 1995; 332: 1393–98.CrossRefGoogle ScholarPubMed
47Haapala, K, Hyytinen, ER, Roiha, M, Laurila, M, Rantala, I, Helin, HJ et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Investig 2001; 81: 1647–51.CrossRefGoogle ScholarPubMed
48Feldman, BJ, Feldman, D. The development of androgen-independent prostate cancer. Nature Rev Cancer 2001; 1: 34–45.CrossRefGoogle ScholarPubMed